Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.

ABSTRACT: Gliomas are the most common primary brain tumors in adults. A diffuse infiltrative growth pattern and high resistance to therapy make them largely incurable, but there are significant differences in the prognosis of patients with different subtypes of glioma. Mutations in isocitrate dehydrogenase (IDH) have been recognized as an important biomarker for glioma classification and a potential therapeutic target. However, current clinical methods for detecting mutated IDH (mIDH) require invasive tissue sampling and cannot be used for follow-up examinations or longitudinal studies. PET imaging could be a promising approach for non-invasive assessment of the IDH status in gliomas, owing to the availability of various mIDH-selective inhibitors as potential leads for the development of PET tracers

SUBMITTER: Neumaier F 

PROVIDER: S-EPMC10096429 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature